Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease
Mov Disord
.
2022 Mar;37(3):654.
doi: 10.1002/mds.28936.
Epub 2022 Jan 29.
Authors
Matthew Surface
1
,
Manisha Balwani
2
,
Cheryl Waters
1
,
Alexander Haimovich
1
,
Ziv Gan-Or
3
4
5
,
Karen S Marder
1
,
Tammy Hsieh
6
,
Linxia Song
6
,
Shalini Padmanabhan
7
,
Frank Hsieh
6
,
Kalpana M Merchant
8
,
Roy N Alcalay
1
Affiliations
1
Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
2
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
3
The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Quebec, Canada.
4
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
5
Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
6
Nextcea, Inc, Woburn, Massachusetts, USA.
7
The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
8
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
PMID:
35092096
DOI:
10.1002/mds.28936
No abstract available
Publication types
Letter
Comment
MeSH terms
Biomarkers
Glucosylceramidase
Humans
Parkinson Disease* / diagnosis
Psychosine / analogs & derivatives
Substances
Biomarkers
Psychosine
sphingosyl beta-glucoside
Glucosylceramidase
Grants and funding
K02NS080915/NS/NINDS NIH HHS/United States
UL1 TR000040/NS/NINDS NIH HHS/United States